Socioeconomic Disparities in Lung Cancer Screening Participation

• by Sara Delilovic, Diego Yacaman Mendez, Nina Markholm Nordgren, Gunnar Wagenius, Anne Richter

• July 16, 2026

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

• by Lauren Averett Byers, Byoung Chul Cho, Alissa J. Cooper, Anne C. Chiang, Ji-Youn Han, Muhammad Furqan, Afshin Dowlati, Daniel Morgensztern, Kyriakos P. Papadopoulos, Noura J. Choudhury, María Vieito, Jair Bar, Joo-Hang Kim, Wallace Akerley, Tae Min Kim, Young-Chul Kim, Luis Paz-Ares, Myung-Ju Ahn, Hiroshi Yokouchi, Darius Meiman, Wijith Munasinghe, Oluwadamilola Ogunyankin, Nadine Jahchan, Song Wang, Cristiano Ferlini, Randy R. Robinson, Frederick J. Kohlhapp, Tammy Palenski, Guillermo Rivell, Pooja Hingorani, Sreenivasa Chandana

• June 1, 2026

Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction

• by Wen Xiao, Qingfei Kong

• July 1, 2026

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

• June 9, 2026

• 5 min